Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

Dow Jones

03/30

1039 GMT - Sanofi shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. "Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks," analysts at UBS say in a note. Sanofi says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 30, 2026 06:40 ET (10:40 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2623965319"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623965319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623965319?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623965319","market":"sh","top_or_hot":-1,"title":"Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-30 18:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"賽諾菲安萬特","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2623965319","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623965319","pubTimestamp":1774867200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1039 GMT - Sanofi shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. Sanofi says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi"},"translate_title":"赛诺菲报告第二例癌症病例正在试验后股价下跌——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"SNY":0.9},"content_text":"1039 GMT - Sanofi shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. Sanofi says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 06:40 ET (10:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}